 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | BMS-986234 / BMS, BMS-986278 / BMS, BMS-986020 / BMS
Preclinical, Journal: Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA) antagonists. (Pubmed Central) - Mar 11, 2022
Mixed effects on plasma bile acids in both rat and monkey has made this biomarker not a useful predictor of the hepatobiliary toxicity. In conclusion, the nonclinical data indicate the hepatobiliary toxicity observed clinically and in monkeys administered BMS-986020 is compound specific and not mediated via antagonism of LPA.
- | BMS-986234 / BMS, BMS-986278 / BMS, BMS-986020 / BMS
Journal: Mechanism of hepatobiliary toxicity of the LPA antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278. (Pubmed Central) - Mar 11, 2022
The data indicate that this toxicity was unrelated to LPA antagonism since the mechanisms that likely influenced the adverse clinical outcome of BMS-986020 were not observed with equipotent LPA antagonists BMS-986234 and BMS-986278. This conclusion is consistent with the lack of hepatobiliary toxicity in nonclinical and clinical safety studies with BMS-986278.